Roche Immunotherapy Combination Increases Lung Cancer Survival - Study | Latest News RSS feed

Roche Immunotherapy Combination Increases Lung Cancer Survival - Study - Latest News


Roche immunotherapy combination increases lung cancer survival-study

May 16 (Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination with... read more

Combination therapy doubles survival in metastatic lung cancer

The immunotherapy drug pembrolizumab, when combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer ... % in the combination group and 65.8% in the standar... read more

Roche’s lung cancer data look good, so why didn’t the market react to clinical trial results?

Basel, Switzerland-based Roche has announced ... non-squamous non-small cell lung cancer (NSCLC). Roche notes that this is the first time a combination immunotherapy trial has successfully increased p... read more

Looking for another news?


Two trial wins for Roche’s immunotherapy Tecentriq

Roche’s immunotherapy ... as the foremost immunotherapy for non-small cell lung cancer, meaning Roche is still playing catch-up in the space. "Initial treatment with this Tecentriq-based combination p... read more


Combo of Merck's Keytruda and chemo show survival benefit in mid-stage lung cancer study; shares ahead 1%

Merck (MRK +0.8%) looks like the one to beat in the race to develop cancer combination therapies. Data from a mid-stage lung cancer study ... chemotherapy increased overall survival (OS) in lung cance... read more

This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

Adding Roche’s (rhhvf) immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients ... the Tecentriq combination compared with 19.3% in the Avastin-chemo group, is still awai... read more

What's New in Lung Cancer Imaging: RSNA Round-up

Another interesting study from Japan (Kaira et al.) showed increased baseline FDG ... further improve the accuracy of overall survival prognosis." Next-Gen Imaging Given the explosion of immunotherapy ... read more

Roche immunotherapy combination increases lung cancer survival - study

(Reuters) - Roche’s immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tec... read more

Roche immunotherapy combination increases lung cancer survival-study

(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tec... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us